Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUMATRIPTAN AND NAPROXEN SODIUM vs RIZATRIPTAN BENZOATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibiting trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. The combination provides synergistic relief for migraine by targeting both neurogenic inflammation and vasodilation.
Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.
Acute treatment of migraine with or without aura in adults,Off-label: Acute treatment of cluster headache (sumatriptan component)
Acute treatment of migraine with or without aura in adults.,Acute treatment of migraine with or without aura in pediatric patients 6 to 17 years of age.
Sumatriptan 85 mg/naproxen sodium 500 mg orally at onset of migraine; maximum one tablet per 24 hours.
5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.
Sumatriptan: 2.5 hours (range 2-4 hours); Naproxen: 12-17 hours (mean 14 hours). Clinical context: Sumatriptan half-life supports short dosing interval; Naproxen half-life allows twice-daily dosing for migraine prevention.
2-3 hours in adults; clinically, no significant accumulation with multiple dosing.
Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A) to an indoleacetic acid metabolite. Naproxen sodium is metabolized by hepatic CYP enzymes (CYP1A2, CYP2C9) and other pathways, with glucuronidation.
Primarily metabolized by monoamine oxidase A (MAO-A) via oxidative deamination; minor metabolism by aldehyde oxidase. The major metabolite is the inactive N-desmethyl rizatriptan.
Sumatriptan: 57% renal (22% unchanged), 38% fecal; Naproxen: 95% renal (mostly as conjugated metabolites, <5% unchanged), <5% fecal.
Primarily hepatic metabolism via monoamine oxidase-A, with ~14% excreted unchanged in urine; total recovery of radioactivity in urine is ~82% (30% unchanged drug, 52% metabolites) and ~9% in feces over 24 hours.
Sumatriptan: 14-21% (primarily albumin); Naproxen: >99% (albumin, extensively bound).
14%
Sumatriptan: 2.4 L/kg (suggests extensive tissue distribution); Naproxen: 0.16 L/kg (confined primarily to plasma and synovial fluid).
140 L (approximately 2 L/kg in adults), indicating extensive tissue distribution.
Sumatriptan: Oral 15% (due to first-pass metabolism), subcutaneous 96%, intranasal 17%; Naproxen: Oral >95% (nearly complete).
Oral: ~45% (due to first-pass metabolism); intranasal: ~42% (compared to subcutaneous sumatriptan); orally disintegrating tablet: ~45%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min); no adjustment recommended for mild to moderate impairment.
No dosage adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Contraindicated in severe hepatic impairment (Child-Pugh class C); not recommended in moderate impairment (Child-Pugh class B); no adjustment for mild (Child-Pugh class A).
Not recommended in patients with severe hepatic impairment (Child-Pugh class C) due to absence of studies. For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; use caution.
Not recommended for patients under 18 years due to safety and efficacy not established.
Children 6-17 years: 5-10 mg orally at onset; may repeat after 2 hours; maximum 30 mg per 24 hours. Weight <40 kg: start 5 mg. Weight ≥40 kg: may use 10 mg.
Not recommended in patients ≥65 years due to increased risk of adverse events; no specific dosing adjustments available.
Elderly patients may have increased risk of adverse effects. Start at 5 mg; use caution with comorbidities and concomitant medications. No specific dose adjustment required; monitor cardiovascular status.
None
None
Cardiovascular risk: Serious cardiovascular events including myocardial infarction, stroke, and coronary vasospasm, especially in patients with risk factors.,Gastrointestinal risk: NSAID-induced GI bleeding, ulceration, and perforation, particularly in elderly or those with prior GI history.,Hypertension: Elevation in blood pressure, including hypertensive crisis.,Serotonin syndrome: Risk when combined with other serotonergic drugs (e.g., SSRIs, MAOIs).,Renal toxicity: NSAIDs may impair renal function.,Anaphylaxis/allergic reactions: Immediate medical attention required.,Withdrawal headache: Overuse may lead to medication-overuse headache.
Risk of myocardial ischemia and/or infarction, coronary artery vasospasm, cerebrovascular events, and increased blood pressure. Serotonin syndrome (especially when co-administered with other serotonergic drugs). Use only after clear diagnosis of migraine; not for use in hemiplegic or basilar migraine. Caution in patients with risk factors for coronary artery disease. Avoid use within 24 hours of other 5-HT1 agonists or ergotamine derivatives. Monitor for signs/symptoms of serotonin syndrome.
History of coronary artery disease, myocardial infarction, or ischemic heart disease,Coronary vasospasm (Prinzmetal's angina),Uncontrolled hypertension,Cerebrovascular disease (stroke or transient ischemic attack),Peripheral vascular disease,Hemiplegic or basilar migraine,Severe hepatic impairment,Third trimester of pregnancy,History of GI bleeding or perforation related to NSAID use,Active peptic ulcer disease,Concurrent use of MAO-A inhibitors or within 2 weeks of discontinuation,Hypersensitivity to sumatriptan, naproxen, or aspirin/other NSAIDs (including aspirin triad)
History of ischemic heart disease (angina, myocardial infarction, silent ischemia), coronary artery vasospasm (Prinzmetal's angina), or other significant cardiovascular disease. Uncontrolled hypertension. Hemiplegic or basilar migraine. Use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication. Concurrent use or within 2 weeks of monoamine oxidase inhibitor (MAOI) therapy. Known hypersensitivity to rizatriptan or any component. Severe hepatic impairment (Child-Pugh class C).
No specific food restrictions, but avoid alcohol due to increased GI bleeding risk. May take with or without food. Food may delay absorption slightly but does not affect efficacy.
No significant food interactions. However, high-fat meals may delay absorption. Avoid alcohol as it may worsen headaches or increase side effects.
Sumatriptan: Human data do not show increased risk of major birth defects overall, but limited data in first trimester; animal studies show embryo/fetal toxicity at high doses. Naproxen: NSAIDs should be avoided after 30 weeks gestation due to risk of premature closure of ductus arteriosus and oligohydramnios; avoid in first and second trimesters unless clearly needed due to potential association with cardiac defects and miscarriage.
Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats or rabbits but was associated with embryo-fetal toxicity at maternotoxic doses. Use only if potential benefit justifies potential risk to the fetus. First trimester: no specific data, but theoretical risk of vasoconstriction. Second and third trimesters: may cause uterine contractions or reduced uterine blood flow.
Sumatriptan: Excreted in breast milk in low amounts (M/P ratio 4.9); infant dose about 3.5% of maternal weight-adjusted dose; limited data show no adverse effects. Naproxen: Excreted in breast milk (M/P ratio 0.01-0.17); infant dose about 1-2% of maternal dose; use caution in premature infants or with prolonged use due to potential NSAID effects.
Rizatriptan is excreted in human milk at very low levels; the milk-to-plasma ratio is approximately 0.07. The estimated infant dose is about 3% of the maternal weight-adjusted dose. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for rizatriptan and potential adverse effects on the breastfed infant.
Sumatriptan: No dose adjustment recommended based on pharmacokinetic changes; however, consider lowest effective dose and avoid if possible first trimester. Naproxen: Avoid in pregnancy; if essential, use lowest effective dose for shortest duration. No pharmacokinetic data necessitating dose adjustment, but third trimester use is contraindicated.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume, altered metabolism) may reduce exposure. Use lowest effective dose for shortest duration. If migraine severity warrants, standard dosing (5-10 mg oral, may repeat after 2 hours, max 30 mg/24h) may be used.
Combination tablet provides dual mechanism: sumatriptan (5-HT1B/1D agonist) and naproxen sodium (NSAID). Onset within 30 minutes. Maximum single dose: sumatriptan 85 mg/naproxen 500 mg. Risk of serotonin syndrome with other serotonergic drugs. Avoid in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, or history of GI bleeding. Contraindicated within 24 hours of ergot alkaloids or other triptans. Renal dose adjustment necessary for Cr Cl <30 m L/min. Use lowest effective dose for shortest duration. Assess cardiovascular risk before prescribing. May cause drowsiness or dizziness.
Rizatriptan is a selective 5-HT1B/1D receptor agonist used for acute migraine. Onset of action is rapid (30 min). Maximum daily dose is 30 mg (oral tablets) or 30 mg (ODT). Do not use within 24 hours of other triptans or ergotamines. Contraindicated in patients with ischemic heart disease, uncontrolled hypertension, or basilar/hemiplegic migraine. Avoid in patients with moderate/severe hepatic impairment. ODT dissolves quickly and can be taken without water, useful for patients with nausea.
Take at the first sign of migraine; do not use to prevent migraines.,Do not exceed one tablet in 24 hours; wait at least 2 hours between doses.,Avoid alcohol, as it may increase risk of stomach bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, aspirin) unless directed.,Seek emergency if chest pain, shortness of breath, sudden severe stomach pain, black/bloody stools, or signs of allergic reaction occur.,Avoid driving or operating machinery if drowsy or dizzy.,Notify doctor if you have heart disease, high blood pressure, liver/kidney disease, or are pregnant/nursing.
Take at the first sign of migraine headache; it will not prevent attacks.,Do not exceed 30 mg in any 24-hour period (separate doses by at least 2 hours).,If first dose does not work, do not take a second dose for the same attack without consulting your doctor.,Seek emergency care if you experience chest pain, shortness of breath, or sudden severe headache.,Inform your doctor if you have heart disease, high blood pressure, or are taking MAOIs (within 2 weeks) or other migraine medications.
"Naproxen and meloxicam are both nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins, prostacyclin, and thromboxanes. Concomitant use increases the risk of dose-dependent adverse effects, particularly gastrointestinal ulceration, bleeding, and perforation, as well as renal impairment, due to additive inhibition of protective prostaglandins in the gut and kidney. Clinically, this combination may result in acute kidney injury, anemia from occult gastrointestinal bleeding, or life-threatening perforation, especially in elderly patients or those with pre-existing renal disease or peptic ulcer history."
"Bevantolol, a beta-1 selective adrenergic receptor antagonist, reduces cardiac output and suppresses renin release, thereby lowering blood pressure. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins and enhanced sodium and water retention. The net effect is an attenuation of bevantolol's antihypertensive efficacy, potentially resulting in elevated blood pressure and reduced cardiovascular protection."
"Betaxolol, a beta-1 selective adrenergic receptor antagonist, may reduce the antihypertensive efficacy of naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Naproxen inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the renal and vascular endothelium. This can result in sodium and fluid retention, increased systemic vascular resistance, and blunting of the blood pressure-lowering effects of beta-blockers like betaxolol, potentially compromising hypertension control."
"Co-administration of rizatriptan, a selective 5-HT1B/1D receptor agonist, with sertraline, a selective serotonin reuptake inhibitor (SSRI), increases the risk of serotonin syndrome due to additive serotonergic effects. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients should be monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, especially during initiation or dose escalation."
"Paroxetine, a selective serotonin reuptake inhibitor (SSRI), inhibits the metabolism of rizatriptan, a triptan used for migraine, via CYP1A2 and possibly other pathways, leading to increased rizatriptan plasma concentrations. This elevates the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular abnormalities, autonomic instability, and altered mental status. Clinically, patients may experience symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, requiring prompt recognition and management."
"The combination of rizatriptan, a serotonin 5-HT1B/1D receptor agonist, and ziprasidone, an atypical antipsychotic with serotonergic activity (5-HT2A antagonist and weak serotonin reuptake inhibition), may increase the risk of serotonin syndrome. Serotonin syndrome is a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This additive serotonergic effect occurs through overlapping mechanisms, including enhanced 5-HT1A and 5-HT2A receptor activation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUMATRIPTAN AND NAPROXEN SODIUM vs RIZATRIPTAN BENZOATE, answered by our medical review team.
SUMATRIPTAN AND NAPROXEN SODIUM is a 5-HT1 Agonist that works by Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibiting trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. The combination provides synergistic relief for migraine by targeting both neurogenic inflammation and vasodilation.. RIZATRIPTAN BENZOATE is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUMATRIPTAN AND NAPROXEN SODIUM and RIZATRIPTAN BENZOATE depend on the specific clinical indication. These are both 5-HT1 Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUMATRIPTAN AND NAPROXEN SODIUM is: Sumatriptan 85 mg/naproxen sodium 500 mg orally at onset of migraine; maximum one tablet per 24 hours.. The standard adult dose of RIZATRIPTAN BENZOATE is: 5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUMATRIPTAN AND NAPROXEN SODIUM and RIZATRIPTAN BENZOATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUMATRIPTAN AND NAPROXEN SODIUM is classified as Category D/X. Sumatriptan: Human data do not show increased risk of major birth defects overall, but limited data in first trimester; animal studies show embryo/fetal toxicity at high doses. Nap. RIZATRIPTAN BENZOATE is classified as Category D/X. Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.